You are viewing a historical snapshot of United States (NYSE / Nasdaq). These figures are a preview to show what TradeTidings covers. Live, continuously updated United States sentiment and stock impact is a Pro feature.
Get live United States data with ProAbbott Laboratories (ABT)
4 stories published on ABT since June 2026. See all coverage.
News sentiment trend
Counts of positive, neutral, and negative news items over the last 90 days. Not a price chart.
Informational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
Sentiment timeline
How news sentiment on Abbott Laboratories (ABT) has built up over time. Each bar sums the direction of every story TradeTidings published in the period, weighted by how influential we rated it, not just a plain count, so a single high-influence negative story can outweigh several small positive ones. Hover a bar for its exact figures, or click one to filter the stories below to that period. Our own original analysis, not a copied index or a price chart, and not a prediction.
Why this reading
The recent items weighing most on this reading, by direction and influence.
Abbott Stock: ABT Hits Three Month High After Raising 2026 Profit Outlook
Direct news · High influence · Long term
Abbott Stock: ABT Raises 2026 EPS Outlook to $5.45-$5.60 After Q2 Beat
Direct news · Medium influence · Long term
Abbott Secures CE Mark for World's First Dual Glucose-Ketone Continuous Monitoring Device
Direct news · Medium influence · Long term
Abbott Laboratories Q1 Sales and Guidance Put ABT Fair Value Back in Focus
Direct news · Medium influence · Short term
Direct news
The most recent stories naming ABT directly, across all of our coverage.
Abbott Stock: ABT Hits Three Month High After Raising 2026 Profit Outlook
Abbott Stock: ABT Raises 2026 EPS Outlook to $5.45-$5.60 After Q2 Beat
Abbott Laboratories Q1 Sales and Guidance Put ABT Fair Value Back in Focus
Abbott Secures CE Mark for World's First Dual Glucose-Ketone Continuous Monitoring Device
Indirect drivers in the news
Macro, commodity, FX and regulatory forces that have moved ABT, with the stories behind each.
No indirect-driver news for ABT in our coverage yet.
Also monitored for ABT (no news in our coverage yet): FDA approvals & trial outcomes, Drug pricing / FDA / IRA.
See the full picture
Sign up free to track ABT, unlock full history and the complete driver breakdown, and get alerts when sentiment shifts.
Track ABT for freeInformational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.